So talk to us about the science behind the strategy and why you think it could overcome some of the challenges that have limited us to date.

Of course.

Yeah, absolutely.

So I wanted to first start actually by talking about regulatory T cells or Treg cells, as they're called.

Right.

So these are everyone who works in autoimmunity and is an immunologist understands that Tregs are very important because they act like the immune system's brakes.

They prevent the body from attacking its own cells.

So what made these initial tumor types different? the right place to start and what characteristics of the platform give you confidence and really happy about the broad applicability of across multiple solid tumors.